Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: A long-term study

Blood

Volumn 116, Issue 3, 2010, Pages 343-353

  Dammacco, Franco ^a   Tucci, Felicia Anna ^a   Lauletta, Gianfranco ^a   Gatti, Pietro ^a   De Re, Valli ^b   Conteduca, Vincenza ^a   Sansonno, Silvia ^b   Russi, Sabino ^a   Mariggiò, Maria Addolorata ^a   Chironna, Maria ^a   Sansonno, Domenico ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; RITUXIMAB; VIRUS RNA; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; PEGINTERFERON ALFA-2A; PEGINTERFERON ALFA-2B; PRIMER DNA;

ADULT; AGED; ANEMIA; ARTICLE; B LYMPHOCYTE; BLOOD; BONE MARROW; CELL EXPANSION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CRYOGLOBULINEMIA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HEPATITIS C VIRUS; HUMAN; LIVER; LYMPHOCYTE DEPLETION; MALE; NEUTROPENIA; PRIORITY JOURNAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; AMINO ACID SEQUENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; GENETICS; HEPATITIS C; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOLOGY; LONGITUDINAL STUDY; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT OUTCOME; VIROLOGY;

AGED; AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; B-LYMPHOCYTES; BASE SEQUENCE; CRYOGLOBULINEMIA; DNA PRIMERS; DRUG THERAPY, COMBINATION; FEMALE; GENES, IMMUNOGLOBULIN HEAVY CHAIN; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LIVER; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYETHYLENE GLYCOLS; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 77954869956     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-10-245878     Document Type: Article

References (49)

1. Dammacco F, Sansonno D, Piccoli C, Racanelli V, D'Amore FP, Lauletta G. The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and overt B-cell malignancy. Semin Liver Dis. 2000;20(2):143-157. (Pubitemid 30618713)
2. Agnello V, Elfahal M. Cryoglobulin types and rheumatoid factors associated with clinical manifestations in patients with hepatitis C virus infection. Dig Liver Dis. 2007;39(suppl 1):S25-S31. (Pubitemid 47610323)
3. Dammacco F, Sansonno D, Piccoli C, Tucci FA, Racanelli V. The cryoglobulins: an overview. Eur J Clin Invest. 2001;31(7):628-638.
4. Casato M, Laganà B, Antonelli G, Dianzani F, Bonomo L. Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. Blood. 1991;78(12):3142-3147.
5. Ferri C, Marzo E, Longombardo G, et al. Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood. 1993;81(5):1132-1136.
6. Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med. 1994;330(11):751-756. (Pubitemid 24080221)
7. Dammacco F, Sansonno D, Han JH, et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood. 1994;84(10):3336-3343. (Pubitemid 24352895)
8. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C: Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339(21):1485-1492.
9. Calleja JL, Albillos A, Moreno-Otero R, et al. Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia. Aliment Pharmacol Ther. 1999;13(9):1179-1186. (Pubitemid 29445896)
10. Zuckerman E, Keren D, Slobodin G, et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol. 2000;27(9):2172-2178.
11. Cacoub P, Lidove O, Maisonobe T, et al. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum. 2002;46(12):3317-3326. (Pubitemid 35453543)
12. Cacoub P, Saadoun D, Limal N, Sene D, Lidove O, Piette JC. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum. 2005;52(3):911-915. (Pubitemid 40365115)
13. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39(4):1147-1171.
14. Sansonno D, Tucci FA, Lauletta G, et al. Hepatitis C virus productive infection in mononuclear cells from patients with cryoglobulinaemia. Clin Exp Immunol. 2007;147(2):241-248. (Pubitemid 46096001)
15. Mazzaro C, Zorat F, Caizzi M, et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol. 2005;42(5):632-638. (Pubitemid 40501678)
16. Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum. 2006;54(11):3696-3706. (Pubitemid 44737183)
17. Sansonno D, Dammacco F. Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect Dis. 2005;5(4):227-236. (Pubitemid 40410068)
18. Levine JW, Gota C, Fessler BJ, Calabrese LH, Cooper SM. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol. 2005;32(6):1164-1167. (Pubitemid 40828106)
19. Landau DA, Saadoun D, Halfon P, et al. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum. 2008;58(2):604-611. (Pubitemid 351294898)
20. Sansonno D, De Vita S, Iacobelli AR, Cornacchiulo V, Boiocchi M, Dammacco F. Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia. J Immunol. 1998;160(7):3594-3601. (Pubitemid 28164756)
21. Racanelli V, Sansonno D, Piccoli C, D'Amore FP, Tucci FA, Dammacco F. Molecular characterization of B cell clonal expansions in the liver of chronically hepatitis C virus-infected patients. J Immunol. 2001;167(1):21-29. (Pubitemid 32567756)
22. Sansonno D, Lauletta G, De Re V, et al. Intrahepatic B cell clonal expansions and extrahepatic manifestations of chronic HCV infection. Eur J Immunol. 2004;34(1):126-136. (Pubitemid 38111528)
23. Vallat L, Benhamou Y, Gutierrez M, et al. Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection. Arthritis Rheum. 2004;50(11):3668-3678. (Pubitemid 39488696)
24. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435-445. (Pubitemid 24030569)
25. Sailler L. Rituximab off label use for difficult-to-treat auto-immune diseases: reappraisal of benefits and risks. Clin Rev Allergy Immunol. 2008;34(1):103-110.
26. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood. 2003;101(10):3818-3826. (Pubitemid 36857852)
27. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. 2003;101(10):3827-3834. (Pubitemid 36857853)
28. Lamprecht P, Lerin-Lozano C, Merz H, et al. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis. 2003;62(12):1230-1233. (Pubitemid 37500635)
29. Quartuccio L, Soardo G, Romano G, et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford). 2006;45(7):842-846. (Pubitemid 43985372)
30. Roccatello D, Baldovino S, Rossi D, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant. 2004;19(12):3054-3061. (Pubitemid 40057628)
31. Lake-Bakaar G, Dustin L, McKeating J, Newton K, Freeman V, Frost SD. Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease. Blood. 2007;109(2):845-846. (Pubitemid 46105993)
32. Terrier B, Saadoun D, Sene D, et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. Arthritis Rheum. 2009;60(8):2531-2540.
33. Carusone SC, Goldsmith CH, Smieja M, Loeb M. Summary measures were a useful alternative for analyzing therapeutic clinical trial data. J Clin Epidemiol. 2006;59(4):387-392.
34. Schiff M. A rationale for the use of summary measurements for the assessment of the effects of rheumatoid arthritis therapies. Clin Ther. 2003;25(3):993-1001. (Pubitemid 36459703)
35. Ross RS, Viazov SO, Hoffmann S, Roggendorf M. Performance characteristics of a transcription-mediated nucleic acid amplification assay for qualitative detection of hepatitis C virus RNA. J Clin Lab Anal. 2001;15(6):308-313. (Pubitemid 33097025)
36. Hu YW, Balaskas E, Furione M, et al. Comparison and application of a novel genotyping method, semiautomated primer-specific and mispair extension analysis, and four other genotyping assays for detection of hepatitis C virus mixed-genotype infections. J Clin Microbiol. 2000;38(8):2807-2813. (Pubitemid 30640554)
37. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22(6):696-699.
38. Hofmann WP, Dries V, Herrmann E, Gartner B, Zeuzem S, Sarrazin C. Comparison of transcription mediated amplification (TMA) and reverse transcription polymerase chain reaction (RTPCR) for detection of hepatitis C virus RNA in liver tissue. J Clin Virol. 2005;32(4):289-293. (Pubitemid 40386562)
39. Bernardin F, Tobler L, Walsh I, Williams JD, Busch M, Delwart E. Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia. Hepatology. 2008;47(5):1446-1452. (Pubitemid 351702728)
40. Sansonno D, Lauletta G, Montrone M, Tucci FA, Nisi L, Dammacco F. Virological analysis and phenotypic characterization of peripheral blood lymphocytes of hepatitis C virus-infected patients with and without mixed cryoglobulinaemia. Clin Exp Immunol. 2006;143(2):288-296.
41. Trendelenburg M, Schifferli JA. Cryoglobulins are not essential. Ann Rheum Dis. 1998;57(1):3-5.
42. van Oers MH. Rituximab maintenance therapy: a step forward in follicular lymphoma. Haematologica. 2007;92(6):826-833. (Pubitemid 350161580)
43. Meersseman W, Lagrou K, Sciot R, et al. Rapidly fatal Acanthamoeba encephalitis and treatment of cryoglobulinemia. Emerg Infect Dis. 2007;13(3):469-471.
44. Sansonno D, Carbone A, De Re V, Dammacco F. Hepatitis C virus infection, cryoglobulinaemia, and beyond. Rheumatology (Oxford). 2007;46(4):572-578. (Pubitemid 46523298)
45. Fabris M, Quartuccio L, Sacco S, et al. B-lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection. Rheumatology (Oxford). 2007;46(1):37-43.
46. Sansonno D, Tucci FA, Troiani L, et al. Increased serum levels of the chemokine CXCL13 and upregulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis. Blood. 2008;112(5):1620-1627.
47. Looney RJ, Anolik J, Sanz I. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol. 2004;16(3):180-185. (Pubitemid 38530483)
48. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360(18):1827-1838.
49. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360(18):1839-1850.